Your browser is no longer supported. Please, upgrade your browser.
Settings
XON Intrexon Corporation daily Stock Chart
XON [NYSE]
Intrexon Corporation
Index- P/E- EPS (ttm)-1.04 Insider Own0.50% Shs Outstand121.32M Perf Week-4.98%
Market Cap2.18B Forward P/E- EPS next Y-0.70 Insider Trans-0.75% Shs Float119.70M Perf Month-7.38%
Income-123.20M PEG- EPS next Q-0.23 Inst Own78.50% Short Float16.02% Perf Quarter-21.73%
Sales203.20M P/S10.71 EPS this Y-107.90% Inst Trans-6.13% Short Ratio21.66 Perf Half Y-7.19%
Book/sh4.60 P/B3.90 EPS next Y19.50% ROA-13.00% Target Price38.50 Perf Year-32.11%
Cash/sh1.30 P/C13.85 EPS next 5Y- ROE-22.00% 52W Range17.03 - 32.58 Perf YTD-25.46%
Dividend- P/FCF- EPS past 5Y39.10% ROI-21.30% 52W High-44.94% Beta1.44
Dividend %- Quick Ratio2.20 Sales past 5Y87.80% Gross Margin69.50% 52W Low5.31% ATR0.62
Employees832 Current Ratio2.40 Sales Q/Q3.60% Oper. Margin-63.10% RSI (14)40.45 Volatility3.34% 3.23%
OptionableYes Debt/Eq0.02 EPS Q/Q62.50% Profit Margin-60.60% Rel Volume0.79 Prev Close17.99
ShortableYes LT Debt/Eq0.01 EarningsNov 08 AMC Payout- Avg Volume885.22K Price17.94
Recom2.00 SMA20-5.31% SMA50-6.13% SMA200-16.57% Volume702,546 Change-0.28%
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
Jan-23-15Reiterated Mizuho Buy $30 → $32
Sep-03-13Initiated Mizuho Buy $30
Sep-03-13Initiated Barclays Equal Weight $25
Oct-16-17 04:13PM  Intrexon Corporation Enters into $100 Million Preferred Stock Equity Facility PR Newswire
08:00AM  Intrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution PR Newswire
07:00AM  ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors GlobeNewswire
Oct-12-17 07:00AM  ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology GlobeNewswire
Oct-11-17 08:41AM  Oxitec do Brasil Receives Prestigious Award for Innovation and Impact PR Newswire
Oct-09-17 08:03AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Oct-06-17 08:19PM  Intrexon Corporation (XON): How Does It Impact Your Portfolio? Simply Wall St. -5.98%
11:11AM  ETFs with exposure to Intrexon Corp. : October 6, 2017 Capital Cube
11:05AM  Analysts Are Expecting Gas Fermentation to Be Huge for Intrexon. Here's Why They're Wrong. Motley Fool
Oct-05-17 08:09AM  Intrexon Corp. breached its 50 day moving average in a Bullish Manner : XON-US : October 5, 2017 Capital Cube
Oct-04-17 01:00PM  Transfer of Regulatory Jurisdiction for Oxitec's Self-limiting Friendly Aedes in the United States PR Newswire
Oct-03-17 08:03AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Oct-02-17 04:30PM  Fibrocell to Present at 2017 Cell & Gene Meeting on the Mesa GlobeNewswire
Oct-01-17 07:03AM  5 Incredible Synthetic Biology Holy Grails That Could Change the World Motley Fool
Sep-28-17 04:32PM  ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer GlobeNewswire
Sep-26-17 08:00AM  Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire
Sep-25-17 10:48AM  ETFs with exposure to Intrexon Corp. : September 25, 2017 Capital Cube
Sep-20-17 07:27AM  All You Need To Know About Intrexon Corporations (XON) Financial Health Simply Wall St.
Sep-19-17 11:00AM  Oxitec to Build State-of-the-Art Mosquito Egg Production Unit PR Newswire
Sep-18-17 08:00AM  ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting GlobeNewswire
Sep-14-17 07:32PM  ETFs with exposure to Intrexon Corp. : September 14, 2017 Capital Cube
Sep-13-17 11:50AM  Intrexon Corp. :XON-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
11:00AM  Is Intrexon Corporation Stock Now a Bargain? Motley Fool
Sep-05-17 07:00AM  ZIOPHARM to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
03:00AM  Oxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials PR Newswire
Sep-01-17 09:02AM  The Simple Reason I Won't Buy Intrexon Motley Fool
07:05AM  ZIOPHARM Oncology to Participate at Upcoming CAR-TCR Summit GlobeNewswire
Aug-31-17 04:01PM  Intrexon to Participate in Upcoming Investor Conferences PR Newswire
08:07AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Aug-30-17 08:02AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Aug-22-17 08:04AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Aug-21-17 01:43PM  Weekly CEO Buys Highlights GuruFocus.com
Aug-14-17 11:15AM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares GuruFocus.com -5.60%
Aug-12-17 10:25PM  Edited Transcript of XON earnings conference call or presentation 9-Aug-17 9:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 09:34AM  Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth Motley Fool +5.31%
08:00AM  Today's Research Reports on Trending Tickers: NetEase Inc. and Intrexon Corporation ACCESSWIRE
Aug-10-17 04:28PM  Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss Zacks -11.06%
Aug-09-17 04:05PM  Intrexon Announces Second Quarter and First Half 2017 Financial Results PR Newswire
08:05AM  See what the IHS Markit Score report has to say about Intrexon Corp. Markit
Aug-04-17 04:30PM  AquaBounty Technologies, Inc. Results for the second quarter and first half ended June 30, 2017 GlobeNewswire
09:08AM  Here's How Intrexon Might Prove Me Wrong Motley Fool
Aug-02-17 10:26AM  What's in Store for Intrexon (XON) in this Earnings Season? Zacks
08:00AM  Intrexon to Announce Second Quarter and First Half 2017 Financial Results on August 9th PR Newswire
08:00AM  Fibrocell to Host Conference Call and Webcast on Wednesday, August 9, 2017 to Discuss Second Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
Jul-31-17 08:12PM  Intrexon Corp. Value Analysis (NYSE:XON) : August 1, 2017 Capital Cube
04:05PM  ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities GlobeNewswire
Jul-24-17 07:00AM  ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET GlobeNewswire
Jul-17-17 10:04AM  Intrexon Corp. breached its 50 day moving average in a Bearish Manner : XON-US : July 17, 2017 Capital Cube
Jul-12-17 08:10AM  3 Biggest Challenges Facing This Billionaire-Led Stock Motley Fool
Jul-11-17 10:00AM  Oxitec Launching Friendly Aedes Project in Juiz de Fora, Brazil PR Newswire
06:00AM  7 Wacky Sources of Alternative Energy Motley Fool
Jul-10-17 03:32PM  ETFs with exposure to Intrexon Corp. : July 10, 2017 Capital Cube
12:26PM  Why Intrexon Stock Rose 10.4% in June Motley Fool
Jul-06-17 08:30AM  Oxitec's Friendly Aedes Mosquito Receives Positive Evaluation for European Standard in relation to Human Health and the Environment PR Newswire
Jun-29-17 03:30PM  Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen PR Newswire
12:08PM  Investors slowly start to push climate change up their agenda Reuters
Jun-26-17 05:16PM  ETFs with exposure to Intrexon Corp. : June 26, 2017 Capital Cube
Jun-21-17 11:15AM  What Will Happen to Intrexon's Natural Gas-to-Chemicals Business? Motley Fool
Jun-16-17 04:27PM  ETFs with exposure to Intrexon Corp. : June 16, 2017 Capital Cube
10:05AM  3 Stocks Billionaires Own Motley Fool
09:15AM  Intrexon Integrates Leading Adenoviral Gene Delivery Technology with Completion of GenVec Acquisition PR Newswire
Jun-15-17 06:12AM  BP's Dudley seen reigning for years to restore major's might Reuters
03:07AM  Why Is Intrexon (XON) Down 4.1% Since the Last Earnings Report? Zacks
Jun-14-17 09:42AM  Intrexon Corp. :XON-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-13-17 07:00AM  Intrexon and Johnson Matthey Collaborate on Fermentative Production of Peptide-based Active Pharmaceutical Ingredients PR Newswire
07:00AM  AquaBounty Acquires Fish Farming Facility in Indiana PR Newswire
Jun-12-17 08:00AM  Fibrocell Receives Rare Pediatric Disease Designation from FDA for FCX-013 for Treatment of Localized Scleroderma GlobeNewswire
Jun-08-17 08:00AM  Fibrocell Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire
Jun-05-17 02:15PM  ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting GlobeNewswire
Jun-02-17 11:49AM  Four Stocks that Could be Affected by the Paris Agreement Decision Investopedia
07:00AM  ZIOPHARM to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-31-17 08:00AM  Intrexon's Head of Environment Sector Joins Brazil Investment Forum to Discuss Importance of Vector Control and Economic Impact of Vector-borne Diseases PR Newswire
May-24-17 08:00AM  Intrexon to Present at Upcoming Investor and Industry Conferences PR Newswire
May-18-17 04:01PM  Intrexon Appoints Dr. Mark Carnegie-Brown as CEO of Oxitec PR Newswire
09:08AM  What You Missed in Intrexon's Quarterly Report Motley Fool
May-17-17 05:16PM  ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting GlobeNewswire
08:00AM  Fibrocell to Present at Inaugural Cell & Gene Exchange 2017 GlobeNewswire
05:10AM  Edited Transcript of XON earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-16-17 12:18PM  How these two Tampa Bay companies got the financing to grow their technology American City Business Journals -5.53%
May-15-17 08:00AM  Intrexon to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference PR Newswire +6.34%
May-12-17 04:18PM  Intrexon's First-Quarter 2017 Revenue Lacks Diversification, but Help Is On the Way Motley Fool
10:40AM  Ziopharm Prices Secondary Offering 24/7 Wall St.
09:20AM  ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Himax Technologies and Intrexon Corporation Accesswire
May-11-17 08:16PM  Edited Transcript of XON earnings conference call or presentation 10-May-17 8:30pm GMT Thomson Reuters StreetEvents +20.76%
03:44PM  Intrexon (XON) Q1 Loss Wider than Expected, Revenues Beat Zacks
12:01PM  Why Intrexon Is Soaring Today Motley Fool
May-10-17 04:24PM  Intrexon reports 1Q loss Associated Press
04:05PM  Intrexon Announces First Quarter 2017 Financial Results PR Newswire
08:00AM  Intrexon and Darling to Build Commercial-scale Production of Insect-Based Advanced Feed Ingredients PR Newswire
08:00AM  Fibrocell Reports First Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
May-09-17 09:58AM  Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR Zacks
09:14AM  Fibrocell and Intrexon Announce Two Oral Presentations at the 20th Annual Meeting of the American Society of Gene & Cell Therapy GlobeNewswire
08:00AM  Huvepharma to Utilize Intrexon's Proprietary Fungal Expression Platform to Produce Key Animal Feed Enzyme PR Newswire
May-08-17 09:11AM  Intrexon Corp. breached its 50 day moving average in a Bearish Manner : XON-US : May 8, 2017 Capital Cube -5.88%
08:00AM  Fibrocell Announces Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa GlobeNewswire
May-03-17 08:00AM  Intrexon to Announce First Quarter 2017 Financial Results on May 10th PR Newswire
08:00AM  Fibrocell to Host Conference Call and Webcast on Wednesday, May 10, 2017 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights GlobeNewswire
May-02-17 06:38PM  Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings? Zacks
07:00AM  ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia GlobeNewswire
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and cloning technologies; genetically engineered swine for medical and genetic research; biological insect control solutions; technologies for non-browning apple without the use of any flavor-altering chemical or antioxidant additives; commercial aquaculture products; and artwork, children's toys, and novelty goods that are derived from living organisms or enabled by synthetic biology. The company serves health, food, energy, environment, and consumer sectors. Intrexon Corporation has collaboration and license agreements with Ares Trading S.A.; ZIOPHARM Oncology, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; S & I Ophthalmic, LLC; OvaXon, LLC; Intrexon Energy Partners, LLC; Persea Bio, LLC; Thrive Agrobiotics, Inc.; Intrexon Energy Partners II, LLC; and others. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gupta Vinita DDirectorAug 22Buy17.613,00052,8303,000Aug 23 04:37 PM
SHAPIRO ROBERT BDirectorAug 22Buy17.502,85049,88382,966Aug 23 04:34 PM
Last Andrew J.Chief Operating OfficerAug 14Buy19.992,00039,9802,000Aug 15 01:14 PM
KIRK RANDAL JChief Executive OfficerAug 11Buy18.85132,6252,499,9816,782,622Aug 14 08:57 AM
Nimrodi NirSVP-Corporate DevelopmentAug 11Buy18.753,36963,1697,369Aug 14 08:33 AM
Lehr Donald P.Chief Legal OfficerAug 11Buy18.331,09420,05328,249Aug 11 01:08 PM
Perez Jeffrey ThomasSVP, IP AffairsAug 11Buy17.891,00017,89012,537Aug 11 01:04 PM
MITCHELL DEAN JDirectorAug 11Buy18.335,00091,64018,103Aug 11 01:03 PM
KINDLER JEFFREY BDirectorAug 11Buy18.325,44099,66171,762Aug 15 01:15 PM
Sterling Rick L.Chief Financial OfficerJul 07Option Exercise2.6468,252180,18574,621Jul 10 08:32 AM
KIRK RANDAL J10% OwnerMay 08Sale2.5411,57629,40385,397May 08 05:30 PM
KIRK RANDAL J10% OwnerMay 05Sale2.7085,500230,85087,278May 08 05:30 PM
KIRK RANDAL J10% OwnerMay 04Sale3.7863,892241,629101,171May 08 05:30 PM
KIRK RANDAL J10% OwnerJan 18Buy10.332,421,07325,009,6845,161,247Jan 20 04:56 PM
KIRK RANDAL J10% OwnerDec 29Sale0.4542,00018,900674,169Dec 29 09:36 PM
KIRK RANDAL J10% OwnerDec 28Sale0.4784,62039,771694,246Dec 29 09:36 PM
KIRK RANDAL J10% OwnerDec 27Sale0.5150,40025,704734,696Dec 29 09:36 PM
Perez Jeffrey ThomasSVP, IP AffairsDec 21Option Exercise19.605,10199,98011,537Dec 22 07:24 AM
Sterling Rick L.Chief Financial OfficerDec 20Option Exercise2.653,0007,9506,369Dec 22 07:20 AM
KIRK RANDAL JChief Executive OfficerDec 13Buy28.9034,6061,000,113213,805Dec 14 09:05 AM
LIFFMAN JOEL DSVP, FinanceDec 12Buy28.628,500243,265158,500Dec 13 07:09 AM
Hassan FredDirectorDec 01Buy29.026,900200,2666,900Dec 05 11:14 AM